Apolipoprotein E polymorphism and atherosclerosis

Angiology

Volumn 54, Issue 1, 2003, Pages 59-71

  Kolovou, Genovefa ^a   Daskalova, Deliana ^a   Mikhailidis, Dimitri P ^b  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ATHEROSCLEROSIS; BIOAVAILABILITY; DIAGNOSTIC VALUE; DISEASE COURSE; ETHNOLOGY; GENOTYPE; HEART INFARCTION; HUMAN; MEDICAL RESEARCH; PROTEIN POLYMORPHISM; REVIEW; RISK FACTOR; VASCULAR DISEASE;

EID: 0037274826     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970305400108     Document Type: Review

References (151)

1. Saunders AM, Strittmatter WJ, Schmechel D, et al: Association of apolipoprotein E allele ε4 with lateonset familial and sporadic Alzheimer's disease. Neurology 43:1467-1472, 1993.
2. Myhre A, Tysnes OB: Etiology and genetics of Alzheimer disease. Tidsskr Nor Laegeforen 122:50-53, 2002.
3. Schächter F, Faure-Delanef L, Guénot F, et al: Genetic associations with human longevity at the apo E and ACE loci. Nat Genet 6:29-32, 1994.
4. Jovone T, Kervinen K, Kairaluoma MI, et al: Gallstone cholesterol content is related to apolipoprotein E polymorphism. Gastroenterology 104:1806-1813, 1993.
5. Van Erpecum KJ, Carey MC: Apolipoprotein E4: Another risk factor for cholesterol gallstone formation? Gastroenterology 111:1764-1767, 1996.
6. Kervinen K, Sodervik H, Makela J, et al: Is the development of adenoma and carcinoma in proximal colon related to apolipoprotein E phenotype? Gastroenterology 110:1785-1790, 1996.
7. Zunarelli E, Nicoll JA, Migaldi M, et al: Apolipoprotein E polymorphism and breast carcinoma: Correlation with cell proliferation indices and clinical outcome. Breast Cancer Res Treat 63:193-198, 2000.
8. Zunarelli E, Nicoll JA, Trentini GP: Apolipoprotein E polymorphism and central nervous system tumors: Correlation with cell proliferation indices and clinical outcome. Clin Neuropathol 19:1-6, 2000.
9. Carlin C, Murray L, Graham D, et al: Involvement of apolipoprotein E in multiple sclerosis: Absence of remyelination associated with possession of the Apo E epsilon2 allele. J Neuropathol Exp Neurol 59:361-367, 2000.
10. McCarron MO, Nicoll JA: Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage. Ann NY Acad Sci 903:176-179, 2000.
11. Nicoll JAR, McCarron MO, Weir CJ, et al: Apolipoprotein E polymorphism and in-hospital mortality following intracerebral hemorrhage. Neurology 54(suppl 3):A386-A387, 2000.
12. Grocott HP, Newman MF, El-Moalem H, et al: Apolipoprotein E genotype differentially influences the proinflammatory and antiinflammatory response to cardiopulmonary bypass. J Thorac Cardiovasc Surg 122:622-623, 2001.
13. Broderick J, Lu M, Jackson C, et al: and the NINDS t-PA Stroke Study Group: Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann Neurol 49:736-744, 2001.
14. Ballantyne CM, Herd JA, Stein EA, et al: Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 36:1572-1578, 2000.
15. Corella D, Tucker K, Lahoz C, et al: Alcohol drinking determines the effect of the apo E locus on LDL-cholesterol concentrations in men: The Framingham Offspring Study. Am J Clin Nutr 73:736-745, 2001.
16. Rall SC, Weisgraber KH, Mahley RW: Human apolipoprotein E: The complete amino acid sequence. J Biol Chem 257:4171-4178, 1982.
17. Taira K, Bujo H, Hirayama S, et al: LR11, a mosaic LDL receptor family member, mediates the uptake of Apo E-rich lipoproteins in vitro. Arterioscler Thromb Vasc Biol 21:1501-1506, 2001.
18. Kamboh MI, Aston CE, Ferrell RE, et al: Impact of apolipoprotein E polymorphism in determining interindividual variation in total cholesterol and low-density lipoprotein cholesterol in Hispanics and non-Hispanic whites. Atherosclerosis 98:201-211, 1993.
19. Xhignesse M, Lussier-Cacan S, Sing CF, et al: Influence of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler Thromb 11:1100-1110, 1991.
20. Paik YK, Chang DJ, Reardon CA, et al: Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci USA 82:3445-3449, 1985.
21. Utermann G, Albrecht G, Steinmetz A: Polymorphism of apolipoprotein E. Clin Genet 14:351-358, 1978.
22. Hoffmann MM, Scharnagl H, Koster W, et al: Apolipoprotein E, Baden (Arg(180 → Cys). A new apolipoprotein E variant associated with hypertriglyceridemia. Clin Chim Acta 303:41-48, 2001.
23. Gomes-Coronado D, Alvarez JJ, Entrala A, et al: Apolipoprotein E polymorphism in men and women from a Spanish population: Allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis 147:167-176, 1999.
24. Yoshida H, Hasty AH, Major AS, et al: Isoform-specific effects of apolipoprotein E on atherosclerosis. Gene transduction studies in mice. Circulation 104:2820-2825, 2001.
25. Murphy MM, Vilella E, Ceruelo S, et al: The MTHFR C677T, apo E, and PON55 gene polymorphisms show relevant interactions with cardiovascular risk factors. Clin Chem 48:372-375, 2002.
26. Utermann G, Hardewig A, Zimmer F: Apolipoprotein E phenotypes in patients with myocardial infarction. Hum Genet 65:237-241, 1984.
27. Utermann G, Langenback U, Beisigel U, et al: Genetics of the apolipoprotein E system in man. Am J Hum Genet 32:339-347, 1980.
28. Kuusi T, Nieminen MS, Ehnholm C, et al: Apoprotein E polymorphism and coronary artery disease. Increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis 9:237-241, 1989.
29. Hixson JE: Apolipoprotein E polymorphisms affect atherosclerosis in young males: Pathobiological determinants of atherosclerosis in youth (PDAY) research group. Arterioscler Thromb 11:1237-1244, 1991.
30. van Bockxmeer FM, Mamotte CD: Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet 340:879-880, 1992.
31. Tiret L, de Knijff P, Menzel HJ, et al: Apo E polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS study. European Atherosclerosis Research Study. Arterioscler Thromb 14:1617-1624, 1994.
32. Stengard JH, Zerba KE, Pekkanen J, et al: Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 91:265-269, 1995.
33. Lahoz C, Schaefer E, Cupples LA, et al: Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154: 529-537, 2001.
34. Cumming AM, Robertson FW: Polymorphism at the apoprotein-E locus in relation to risk of coronary disease. Clin Genet 25:310-313, 1984.
35. Eichner JE, Kuller LH, Orchard TJ, et al: Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol 71:160-165, 1993.
36. Luc G, Bard JM, Arveiler D, et al: Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb 14:1412-1419, 1994.
37. Brscic E, Bergerone S, Gagnor A, et al: Acute myocardial infarction in young adults: Prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide syntheses, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up. Am Heart J 139:979-984, 2000.
38. Kolovou G, Yiannakouris N, Malakos J, et al: Association of apolipoprotein E polymorphism with myocardial infarction in Greek patients. Curr Med Res Opin 18:118-124, 2002.
39. Kolovou G, Malakos JS, Hatzaki A, et al: Apolipoprotein E but not angiotensin-converting enzyme polymorphism is associated with myocardial infarction. J Am Coll Cardiol 29:82A, 1997.
40. Hatzaki A, Kolovou G, Hatzivassiliou M, et al: Is there an allelic effect of apolipoprotein E gene polymorphism on plasma lipid parameters in Greek patients with myocardial infarction? Eur Heart J 18(suppl):64, 1997.
41. De Knijff P, Jansen H, Lie KI, et al: Apolipoprotein E4 and coronary artery disease. Lancet 340:1351, 1992.
42. Scuteri A, Bos A, Zonderman A, et al: Is the apoE4 allele an independent predictor of coronary events? Am J Med 110:28-32, 2001.
43. Stengard JH, Weiss KM, Sing CF: An ecological study of association between coronary heart disease mortality rates in men and the relative frequencies of common allelic variations in the gene coding for apolipoprotein E. Hum Genet 103:234-241, 1998.
44. McCarron MO, Delong D, Alberts MJ: Apo E genotype as a risk factor for ischemic cerebrovascular disease: A meta-analysis. Neurology 53:1308-1311, 1999.
45. MacLeod MJ, De Lange RP, Breen G, et al: Lack of association between apolipoprotein E genotype and ischaemic stroke and Scottish population. Eur J Clin Invest 31:570-573, 2001.
46. Couderc R, Mahieux F, Bailleul S, et al: Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease: A case-control study. Stroke 24:661-664, 1993.
47. Slooter AJ, Tang MX, van Duijn CM, et al: Apolipoprotein E epsilon4 and the risk of dementia with stroke: A population-based investigation. JAMA 277:818-821, 1997.
48. Margaglione M, Seripa D, Gravina C, et al: Prevalence of apolipoprotein E alleles in healthy subjects and survivors of ischemic stroke: An Italian casecontrol study. Stroke 29:399-403, 1998.
49. DeCarli C, Reed T, Miller BL, et al: Impact of apolipoprotein E epsilon4 and vascular disease on brain morphology in men from the NHLBI twin study. Stroke 30:1548-1553, 1999.
50. Mahley RW, Rall SC Jr: Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: The Metabolic and Molecular Bases of Inherited Disease, ed. 7, ed. by Scriver CR, Beaudet AL, Sly WS, et al. New York: McGraw-Hill, 1995, pp 1953-1980.
51. De Beer F, Stalenhoef AF, Hoogerbrugge N, et al: Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 - ys) homozygotes is associated with hyperinsulinemia. Arterioscler Thromb Vasc Biol 22:294-299, 2002.
52. Carmena R, Roy M, Roederer G, et al: Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinic and laboratory observations. Atherosclerosis 148:113-124, 2000.
53. Wilson PW, Schaefer EJ, Larson MG, et al: Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 16: 1250-1255, 1996.
54. Kalix B, Meynet MC, Garin MC, et al: The apolipoprotein epsilon2 allele and the severity of coronary artery disease in Type 2 diabetic patients. Diabet Med 18:445-450, 2001.
55. Sing CF, Davingnon J: Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 37:268-285, 1985.
56. Ehnholm C, Lukka M, Kuusi T, et al: Apolipoprotein E polymorphism in the Finnish population: Gene frequencies and relation to lipoprotein concentrations. J Lipid Res 27:227-235, 1986.
57. Dallongeville J, Lussier-Cacan S, Davignon J: Modulation of plasma triglyceride levels by apo E phenotype: A meta-analysis. J Lipid Res 33:447-454, 1992.
58. Deiana L, Pes GM, Carru C, et al: Lack of influence of apolipoprotein E4 on lipoprotein levels in the island population of Sardinia. Eur J Clin Invest 28:290-294, 1998.
59. Aguilar CA, Talavera G, Ordovas JM, et al: The apolipoprotein E4 allele is not associated with an abnormal lipid profile in a Native American population following its traditional lifestyle. Atherosclerosis 142:409-414, 1999.
60. Attila G, Acarturk E, Eskandari G, et al: Effects of apolipoprotein E genotypes and other risk factors on the development of coronary artery disease in Southern Turkey. Clin Chim Acta 312:191-196, 2001.
61. Lehtimaki T, Moilanen T, Aalto-Setala K, et al: Association of apolipoprotein E and B polymorphisms with serum lipids. Ann Med 23:657-662, 1991.
62. Davignon J, Cohn JS, Mabile L, et al: Apolipoprotein E and atherosclerosis: Insight from animal and human studies. Clin Chim Acta 286:115-143, 1999.
63. Ilveskoski E, Jarkvinen O, Sisto T, et al: Apolipoprotein E polymorphism and atherosclerosis: Association of the epsilon4 allele with defects in the internal elastic lamina. Atherosclerosis 153:155-160, 2000.
64. Dreon DM, Peroutkal SJ: Medical utility of apo E allele determination in assessing the need for antioxidant therapy. Med Hypotheses 56:357-359, 2001.
65. Lynch JR, Morgan D, Mance J, et al: Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol 114:107-113, 2001.
66. Stannard AK, Riddell DR, Sacre SM, et al: Cell-derived apolipoprotein E (Apo E) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Biol Chem 276:46011-46016, 2001.
67. Calara F, Silvestre M, Casanada F, et al: Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J Pathol 195:257-263, 2001.
68. Libby P: Molecular bases of the acute coronary syndromes. Circulation 91:2844-2850, 1996.
69. Faber B, Cleutjens K, Niessen R, et al: Identification of genes potentially involved in rupture of human atherosclerotic plaques. Circ Res 89:547-554, 2001.
70. Dallongeville J: Apolipoprotein E: Proprietes physiologiques, polymorphisme et atherosclerose. Sang Thrombose Vaisseaux 5:707-717, 1993.
71. James RW, Boemi MG, Giansanti R, et al: Underexpression of the apolipoprotein E4 isoform in an Italian population. Arterioscler Thromb 13:1456-1459, 1993.
72. Bailleul S, Couderc R, Landais V, et al: Direct phenotyping of human apolipoprotein E in plasma: Application to population frequency distribution in Paris (France). Hum Hered 43:159-165, 1993.
73. Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis 8:1-21, 1988.
74. Eggertsen G, Tegelman R, Ericsson S, et al: Apolipoprotein E polymorphism in a healthy Swedish population: Variation of allele frequency with age and relation to serum lipid concentrations. Clin Chem 39:2125-2129, 1993.
75. Gerdes LU, Jeune B, Ranberg KA, et al: Estimation of apolipoprotein E genotype-specific relative mortality risks from the distribution of genotypes in centenarians and middle-aged men: Apolipoprotein E gene is a "frailty gene," not a "longevity gene." Genet Epidemiol 19:202-210, 2000.
76. Nassar BA, Dunn J, Title LM, et al: Relation of genetic polymorphism of apolipoprotein E, angiotensin converting enzyme, apolipoprotein B-100, and glycoprotein IIIa and early onset coronary heart disease. Clin Biochem 32:275-282, 1999.
77. Frikke-Schmidt R, Tybjaerg-Hansen A, Steffensen R, et al: Apolipoprotein E genotype:epsilon 32 women are protected while epsilon 43 and epsilon 44 men are susceptible to ischemic heart disease. The Copenhagen City Heart Study. J Am Coll Cardiol 35:1192-1199, 2000.
78. Stankovic S, Glisic S, Alavanatic D: The effect of a gender difference in the apolipoprotein E gene DNA polymorphism on serum lipid levels in a Serbian healthy population. Clin Chem Lab Med 38:539-544, 2000.
79. Wilson PWF, Myers RH, Larson MG, et al: Apolipoprotein E alleles, dyslipidemias and coronary heart disease: The Framingham Offspring Study. JAMA 272:1666-1671, 1994.
80. Oh JY, Barrett-Connor E; Rancho Bernardo Study Group. Apolipoprotein E polymorphism and lipid levels differ by gender and family history of diabetes: The Rancho Bernardo Study. Clin Genet 60:132-137, 2001.
81. Newman MF, Laskowitz DT, White WD, et al: Apolipoprotein E polymorphism and age at first coronary bypass graft. Anesth Analg 92:824-829, 2001.
82. van Bockxmeer FM, Mamotte CDS, Gibbons FA, et al: Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty. Circulation 92:2066-2071, 1995.
83. Vauhkonen I, Niskanen L, Ryynanen M, et al: Divergent association of apolipoprotein E polymorphism with vascular disease in patients with NIDDM and control subjects. Diabet Med 14:48-56, 1997.
84. Papadakis JA, Milionis HJ, Press M, et al: Treating dyslipidaemia in non-insulin dependent diabetes mellitus - a special reference to statins. J Diabetes Complic 15:211-226, 2001.
85. Ha SK, Park HS, Kim KW, et al: Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 14:2144-2149, 1999.
86. Soedamah-Muthu SS, Colhoun HM, Taskinen MR, et al: EURODIAB IDDM Complications Study Group. Diabetologia 43:1353-1359, 2000.
87. Marcais C, Bernard S, Merlin M, et al: Severe hypertriglyceridaemia in type II diabetes: Involvement of apo C-III Sst-I polymorphism, LPL mutations and apo E3 deficiency. Diabetologia 43:1346-1352, 2000.
88. Peng DQ, Zhao SP, Wang JL: Lipoprotein (a) and apolipoprotein E epsilon 4 as independent risk factors for ischemic stroke. J Cardiovasc Risk 6:1-6, 1999.
89. Marin DB, Breuer B, Marin ML, et al: The relationship between apolipoprotein E, dementia, and vascular illness. Atherosclerosis 140:173-180, 1998.
90. Zhu L, Fratiglioni L, Guo Z, et al: Incidence of dementia in relation to stroke and the apolipoprotein E epsilon4 allele in the very old. Findings from a population-based longitudinal study. Stroke 31:53-60, 2000.
91. Ferrucci L, Guralnik JM, Pahor M, et al: Apolipoprotein E ε2 allele and risk of stroke in the older population. Stroke 28:2410-2416, 1997.
92. Catto AJ, McCormack LJ, Mansfield MW, et al: Apolipoprotein E polymorphism in cerebrovascular disease. Acta Neurol Scand 101:399-404, 2000.
93. Pedro-Botet J, Senti M, Nogues X, et al: Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein (a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke 23:1556-1562, 1992.
94. Lynch JR, Pineda JA, Morgan D, et al: Apolipoprotein E affects the central nervous system response to injury and development of cerebral edema. Ann Neurol 51:113-117, 2002.
95. Skoog I, Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 13(suppl 3):106-114, 1999.
96. Hillen T, Nieczaj R, Munzberg H, et al: Carotid atherosclerosis, vascular risk profile and mortality in a population-based sample of functionally healthy elderly subjects: The Berlin ageing study. J Intern Med 247:679-688, 2000.
97. Ilveskoski E, Loimaala A, Mercuri MF, et al: Apolipoprotein E polymorphism and carotid artery intima-media thickness in a random sample of middle-aged men. Atherosclerosis 153:147-153, 2000.
98. Horesji B, Spacil J, Ceska R, et al: The independent correlation of the impact of lipoprotein (a) levels and apolipoprotein E polymorphism on carotid artery intima thickness. Int Angiol 19:331-336, 2000.
99. Slooter AJ, Bots ML, Havekes LM, et al: Apolipoprotein E and carotid artery atherosclerosis: The Rotterdam study. Stroke 32:1947-1952, 2001.
100. Rizos E, Mikhailidis DP: Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res 52:199-207, 2001.
101. Mikhailidis DP, Wierzbicki AS (editorial comment): The GREek Atorvastatin and Coronary-heart disease Evaluation (GREACE) study. Curr Med Res Opin 2002; in press.
102. Ilveskoski E, Perola M, Lehtimaki T, et al: Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middleaged men: An autopsy study. Circulation 100:608-613, 1999.
103. Guz G, Nurhan Ozdemir F, Sezer S, et al: Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am J Kidney Dis 36:826-836, 2000.
104. Elisaf M, Mikhailidis DP: Statins and renal function. Angiology 2002; in press.
105. Resnick HE, Rodriguez B, Havlik R, et al: Apo E genotype, diabetes, and peripheral arterial disease in older men: The Honolulu Asia-aging study. Genet Epidemiol 19:52-63, 2000.
106. Milionis HJ, Rizos E, Mikhailidis DP: Smoking diminishes the beneficial effect of statins: Observations from the landmark trials. Angiology 52:575-587, 2001.
107. Senti M, Nogues X, Pedro-Botet J, et al: Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation 85:30-36, 1992.
108. Gerdes LU, Gerdes C, Kervinen K, et al: The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian simvastatin survival study. Circulation 101:1366-1371, 2000.
109. Dallongeville J, Tiret L, Visvikis S, et al: The effect of apo E phenotype and plasma postprandial triglyceride levels in young male adults with and without a familial history of myocardial infarction: The EARS II study. European Atherosclerosis Research Study. Atherosclerosis 145:381-388, 1999.
110. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, et al: Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender-specific manner. Atherosclerosis 158:183-193, 2001.
111. Carmena R, Roederer G, Mailloux H, et al: The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 42:895-901, 1993.
112. Nemeth A, Szakmary K, Kramer J, et al: Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy. Eur J Clin Chem Clin Biochem 33:799-804, 1995.
113. Frikke-Schmidt R: Context dependent and invariant associations between apo E genotype and levels of lipoproteins and risk of ischemic heart disease: A review. Scand J Clin Lab Invest Suppl 233:3-25, 2000.
114. Liberopoulos E, Karabina SA, Tselepis A, et al: Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? Oncology 62:115-120, 2002.
115. Mikhailidis DP, Ganotakis ES, Georgoulias VA, et al: Tamoxifen-induced hypertriglyceridaemia: Seven case reports and suggestions for remedial action. Oncol Reports 4:625-628, 1997.
116. Tammi A, Ronnemaa T, Rask-Nissila L, et al: Apolipoprotein E phenotype regulates cholesterol absorption in healthy 13-month-old-children - The STRIP study. Pediatr Res 50:688-691, 2001.
117. Bernstein MS, Costanza MC, James RW, et al: Physical activity may modulate effects of Apo E genotype on lipid profile. Arterioscler Thromb Vasc Biol 22:133-140, 2002.
118. Hagberg JM, Ferrell RE, Katzel LI, et al: Apolipoprotein E genotype and exercise training-induced increases in plasma high-density lipoprotein (HDL)and HDL2-cholesterol levels in overweight men. Metabolism 48:943-945, 1999.
119. Srinivasan SR, Ehnholm C, Elkasabany A, et al: Apolipoprotein E polymorphism modulates the association between obesity and dyslipidemias during young adulthood: The Bogalusa Heart Study. Metabolism 50:696-702, 2001.
120. Szalai C, Czinner A, Csaszar A: Influence of apolipoprotein E genotypes on serum lipid parameters in a biracial sample of children. Eur J Pediatr 159:257-260, 2000.
121. Lee JH, Tang MX, Schupf N, et al: Mortality and apolipoprotein E in Hispanic, African-American, and Caucasian elders. Am J Med Genet 103:121-127, 2001.
122. Kolovou GD, Daskalova DCh, Hatzivassiliou M, et al: The epsilon 2 and 4 alleles of apolipoprotein e and ischemic vascular events in the Greek population - implications for the interpretation of similar studies. Angiology 2002; in press.
123. Ibanez AM, Caamano MB, Fernandez MVF, et al: Risk factors for cardiovascular and ischaemic heart disease in a Mediterranean country: Preliminary report of the Zaragoza study (ZACARIS-I). Clin Drug Invest 22:241-251, 2002.
124. Papadakis JA, Mikhailidis DP, Winder AF: Lipids and stroke: Neglect of a useful preventive measure? Cardiovasc Res 40:265-271, 1998.
125. Athyros VG, Papageorgiou AA, Mercouris BR, et al: Treatment with Atorvastatin to the national cholesterol educational program goals versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18:220-228, 2002.
126. Batalla A, Alvarez R, Reguero JR, et al: Synergistic effect between apolipoprotein E and angiotensinogen gene polymorphism in the risk for early myocardial infarction. Clin Chem 46:1910-1915, 2000.
127. Larson IA, Ordovas JM, DeLuca C, et al: Association of apolipoprotein (Apo) E genotype with plasma apo E levels. Atherosclerosis 148:327-335, 2000.
128. Wu JH, Lo SK, Wen MS, et al: Characterization of apolipoprotein E genetic variations in Taiwanese: Association with coronary heart disease and plasma lipid levels. Hum Biol 74:25-31, 2002.
129. Paul A, Calleja L, Camps J, et al: The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci 68:457-465, 2000.
130. Djousse L, Myers RH, Province MA, et al: Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung and Blood Institute Family Heart Study. Stroke 33:1357-1361, 2002.
131. Humphries SE, Talmud PJ, Hawe E, et al: Apolipoprotein ε4 and coronary artery disease in middleaged men who smoke: A prospective study. Lancet 358:115-119, 2001.
132. Stengard JH, Kardia SL, Tervahauta M, et al: Utility of the predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men aged 65 to 84 years is dependent on context defined by Apo E genotype and area of residence. Clin Genet 56:367-377, 1999.
133. Shahmanesh M, Jaleel H, DeSilva Y, et al: Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype. Sex Transm Infec 77:283-286, 2001.
134. Fernandez-Miranda C, Cancelas P, de la Calle A, et al: Changes in phenotypes of apolipoprotein E and apolipoprotein (a) in liver transplant recipients. Clin Transplant 11:325-327, 1997.
135. Nikkila M, Pitkajarvi T, Koivula T, et al: Women have a larger and less atherogenic low-density lipoprotein particle size than men. Atherosclerosis 119:181-190, 1996.
136. Chun S, Min WK, Kim JW, et al: Apolipoprotein E polymorphism and serum lipoprotein (a) concentrations in a Korean male population. Ann Clin Biochem 38(Pt 2):129-134, 2001.
137. Ritter MM, Gewitsch J, Richter WO, et al: Apolipoprotein E polymorphism has no independent effect on plasma levels of lipoprotein (a). Atherosclerosis 131:243-248, 1997.
138. Klausen IC, Gerdes LU, Hansen PS, et al: Effects of apo E gene polymorphism on Lp(a) concentrations depend on the size of apo(a): A study of 466 white men. J Mol Med 74:685-690, 1996.
139. Milionis HJ, Mikhailidis DP, Winder AF: Platelets and lipoprotein (a): A brief review of their role in the pathogenesis of atherothrombosis. Platelets 10:277-284, 1999.
140. Milionis HJ, Winder AF, Mikhailidis DP: Lp(a) and stroke. J Clin Pathol 53:487-496, 2000.
141. Prelevic GM, Kwong P, Byrne DJ, et al: A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 77: 945-951, 2002.
142. Milionis HJ, Elisaf MS, Mikhailidis DP: Platelets and lipid lowering interventions. Platelets 10:357-367, 1999.
143. Jagroop IA, Mikhailidis DP: Angiotensin II can induce and potentiate shape change in human platelets: Effect of losartan. J Hum Hypertens 14:581-585, 2000.
144. Jagroop IA, Mikhailidis DP: Doxazosin, an alpha1adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Human Hypertens 15:203-207, 2001.
145. Tonolo G, Melis MG, Formato M, et al: Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30:980-987, 2000.
146. Borghi C, Veronesi M, Prandin MG, et al: Statins and blood pressure regulation. Curr Hypertens Rep 3:281-288, 2001.
147. Glorioso N, Troffa C, Filigheddu F, et al: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 36:1281-1291, 1999.
148. Papadakis JA, Ganotakis ES, Jagroop IA, et al: Effect of hypertension, and its treatment, on lipid, lipoprotein (a), fibrinogen and bilirubin levels in patients referred for dyslipidaemia. Am J Hypertens 12:673-681, 1999.
149. Mikhailidis DP, Ganotakis ES, Spyropoulos KA, et al: Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: Response to ciprofibrate or lifestyle advice. Intnl Angiol 17:225-233, 1998.
150. Wierzbicki AS, Mikhailidis DP: Beyond LDL-C - the importance of raising HDL-C. Curr Med Res Opin 18:36-44, 2002.
151. Mikhailidis DP, Wierzbicki AS: HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 16:139-146, 2000.